Published in J Exp Clin Cancer Res on November 01, 2014
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00390299
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | NCT00931931
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | NCT00794131
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer | NCT01935453
rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors | NCT00902122
Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice. J Exp Clin Cancer Res (2015) 0.78
Inactivated Tianjin strain, a novel genotype of Sendai virus, induces apoptosis in HeLa, NCI-H446 and Hep3B cells. Oncol Lett (2016) 0.75
ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells. J Exp Clin Cancer Res (2015) 0.75
Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy. Oncolytic Virother (2016) 0.75
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
Poxvirus pathogenesis. Microbiol Rev (1991) 3.54
THE REPLICATION AND COATING OF VACCINIA DNA. J Mol Biol (1964) 3.30
Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane. J Virol (1990) 3.18
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 2.72
Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. Proc Natl Acad Sci U S A (2007) 2.54
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
The gene encoding the common alpha subunit of the four human glycoprotein hormones. J Mol Appl Genet (1981) 2.48
Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25
Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol (1998) 2.14
RNA editing in Newcastle disease virus. J Gen Virol (1993) 2.14
Transport of vesicular stomatitis virus G protein to the cell surface is signal mediated in polarized and nonpolarized cells. J Cell Biol (1996) 2.06
Vaccinia virus immune evasion. Immunol Rev (1997) 2.03
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest (2005) 1.86
Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J (2009) 1.75
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets (2007) 1.58
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery (2007) 1.54
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 1.54
Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol (1997) 1.54
Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol (2011) 1.54
NMR structure of the 101-nucleotide core encapsidation signal of the Moloney murine leukemia virus. J Mol Biol (2004) 1.53
Adenovirus endocytosis. J Gene Med (2004) 1.52
Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol (1996) 1.52
Measles outbreak associated with an international youth sporting event in the United States, 2007. Pediatr Infect Dis J (2010) 1.49
Reovirus infections in human volunteers. Am J Hyg (1963) 1.43
Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther (2005) 1.40
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab (2008) 1.35
An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am J Public Health Nations Health (1952) 1.34
IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J Immunol (2000) 1.30
Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther (2003) 1.22
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A (2009) 1.19
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18
Virulence of Newcastle disease virus: what is known so far? Vet Res (2011) 1.18
Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer (2009) 1.17
Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol (2008) 1.14
A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods (1994) 1.12
Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther (2012) 1.08
Virus yoga: the role of flexibility in virus host cell recognition. Trends Microbiol (2004) 1.08
Survival discriminants for differentiated thyroid cancer. Am J Surg (1990) 1.07
Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res (2008) 1.06
Nongenital herpes simplex virus. Am Fam Physician (2010) 1.01
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol (2012) 1.00
Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther (2002) 0.99
Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab (1998) 0.99
Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev (1993) 0.99
Reovirus: a targeted therapeutic--progress and potential. Mol Cancer Res (2012) 0.98
Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res (2009) 0.98
Fetal cell carcinogenesis of the thyroid: theory and practice. Semin Cancer Biol (2006) 0.98
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res (2006) 0.98
Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid (1998) 0.97
Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species. J Biol Chem (1988) 0.97
Possible effect of measles on leukaemia. Lancet (1971) 0.97
Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery (2011) 0.97
Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab (2007) 0.95
Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer (2004) 0.93
Overexpression of the c-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest (1995) 0.93
Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology (1997) 0.92
Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res (1999) 0.91
Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res (2008) 0.91
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab (2002) 0.89
Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res (2009) 0.89
Oncolytic viruses & their specific targeting to tumour cells. Indian J Med Res (2012) 0.89
Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract (2013) 0.88
Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck (2010) 0.88
Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther (2012) 0.88
Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res (1999) 0.87
Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx (2004) 0.85
Clinical trials involving the oncolytic virus, reovirus: ready for prime time? Expert Rev Clin Pharmacol (2012) 0.84
Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther (2011) 0.84
Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther (2012) 0.84
Cathepsin B activity and protein levels in thyroid carcinoma, Graves' disease, and multinodular goiters. Thyroid (1999) 0.83
Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur J Endocrinol (2003) 0.82
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther (2014) 0.82
Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther (2004) 0.81
Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid (2001) 0.80
Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol Oncol (2013) 0.79
Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology (2000) 0.78
A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. J Clin Endocrinol Metab (2005) 0.78
A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter. J Exp Clin Cancer Res (2014) 0.78
[The receptors and entry of measles virus: a review]. Sheng Wu Gong Cheng Xue Bao (2013) 0.77
An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. Endocr Relat Cancer (2001) 0.77
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models. Genes Cancer (2011) 0.77
Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol Immunother (1999) 0.76
Interspecies differences in membrane-associated protease activities of thyrocytes and their relevance for thyroid cancer studies. J Exp Clin Cancer Res (2012) 0.76